PumaI was looking at Puma biotech ( PBYI ) . Their SP was down 20% after declaring a loss of $50 million U.S. for the quarter . They have a marketcap of almost 5 billion with annual revenues of $5 million ( a farce ) . A week ago they got a $100 million financing ....$50 million upfront and $50 million at different milestnes . PBYI is just another immuno therapy company getting mediocre results , 27% of slower progression in patients studied with a long list of side effects . Sometimes i think we could give all those patients in those immuno trials two bowls of vegetable soup per day and get the same results . When i look at some of these NASDAQ biotech companies and compare with TLT , the difference is the trial stage and the fact that they're on the NASDAQ . TLT deserves and should have a greater valuation .
Happy saturday